Finance
Results: 697-708 of 38539

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

LANZAJET ANNOUNCES $47M IN NEW CAPITAL AND FIRST CLOSE OF EQUITY ROUND AT $650M PRE-MONEY VALUATION - FURTHER VALIDATING LANZAJET'S SAF TECHNOLOGY AND ENABLING GROWTH







